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comAlthough the prevalence of leprosy has signiﬁcantly decreased
since the introduction of theWorld Health Organization (WHO)
regimen of multidrug therapy (MDT), the incidence remains high,
with a report of approximately 215 656 cases globally in 2013.
Among these, 126 913 cases were reported from India alone [1].
Of a total number of 3196 relapse cases, India alone contributed
486 cases [1]. For most of the infectious diseases for which
secondary prevention is provided by chemotherapy alone, the
emergence of drug resistance ultimately becomes a concern and a
threat to the intervention programmes. However, the ﬁght
against leprosy has been a great success, largely because of the
development of MDT in 1981. The efﬁcacy of MDT in curing
leprosy during the last three decades has brought about a dra-
matic decline in the disease burden in all leprosy-endemic
countries. The annual new case detection rate has also started
to decline in some countries. In India, the prevalence of leprosy
decreased from 4.2 per 10 000 population in 2002 to 0.68 per
10 000 population in 2014 [2]. At this stage of elimination
(<1/10 000), any emergence of drug-resistant Mycobacterium
leprae strains will greatly hamper the control programme of the
country. Previous records reveal that, after almost 30 years of
dapsone monotherapy, dapsone-resistant M. leprae was a major
issue in the leprosy control programme [3].
As rifampicin is the main drug used in MDT and the only
bactericidal drug, it is very important to follow the emergenceClinical Microbiology and Infection © 2015 European Society of Cof rifampicin-resistant mutants in leprosy patients. It has already
been indicated in the recent published literature from Brazil and
India [4,5] that rifampicin-resistant cases are appearing in many
endemic areas of these countries. To overcome the challenge
of containing the disease and to sustain the ongoing declining
trend of leprosy in endemic countries, it is essential to monitor
drug sensitivity patterns in the present settings. The Leprosy
Mission (TLM) Trust India is one of the sentinel centres of the
WHO for surveillance of drug resistance in leprosy. The WHO
sentinel surveillance was undertaken to identify leprosy patients
who already completed an MDT regimen and had relapsed, and
did not show any reduction in the activity of their lesions and
bacteriological indices (BIs), in spite of re-introduction of MDT.
The cases were classiﬁed as multibacillary and paucibacillary,
according to WHO guidelines. Along with these cases, we
enrolled some new cases with high BIs who had not been
treated with any MDT before recruitment, to detect primary
drug resistance. Primary drug resistance refers to patients who
have never been treated for leprosy with MDT.
A total of 1.27 × 105 new leprosy cases were detected in India
during the period 2013–2014, with an annual new case detection
rate of 9.98 per 100 000 population. Of these, approximately
5000 new cases reported to TLM hospitals for treatment.
Written informed consent was obtained from all of the
recruited patients, and the study was approved by the Institu-
tional Ethical Committee. A total of 215 slit-skin scrapings from
relapsed leprosy patients and new patients were obtained be-
tween 2009 and 2014. Slit-skin smears were collected into 70%
ethanol in 1.5-mL Eppendorf tubes. The BI of the slit-skin
smears varied between 1+ and 6+. DNAs of M. leprae were
extracted from slit-skin scrapings with the protocol described
by Lavania et al. [5]. These lysate preparations were further
used for DNA sequencing followed by PCR ampliﬁcation tar-
geting rpoB, folP1, and gyrA [5]. Sterilized distilled water was
used as a negative control for PCR, and the reference strain of
Thai 53 was used as a positive control. The PCR products were
conﬁrmed by 2% agarose gel electrophoresis, and sequence
data were analysed with MEGA 5.1.
Among 215 cases, there were 200 multibacillary cases and
15 paucibacillary cases. Among these 215 cases, there were 184
cases of relapse, 16 new cases, and ﬁve defaulters. Among the
16 new cases, we observed mutations at already reported
codon positions (424, 425, 437, and 438) and at a new codon
position (411) in rpoB in three patients (Table 1). In the rest of
the specimens, we detected secondary resistance mutations in
rpoB at codons 410 (Glu/Val), 411 (Ala/Val), 424
(Val/Gly), 437 (Ser/Gln), 439 (Phe/Leu), 442 (Gln/His),
and 455 (Leu/Pro), which were reported in our previous
study [5]. Among these 16 new cases, seven showed primaryClin Microbiol Infect 2015; 21: e85–e86
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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TABLE 1. Details of primary rifampicin resistance cases
Patient ID Age (years)/sex Classiﬁcation Clinical presentation BI Mutations
PTD 1 60/M LL Nodules all over the body, six nerves involved 4+ Ala411Val; Ala425Gly
PTD 2 36/M LL Inﬁltration and nodules all over the body, bilateral claw hand with shortening
of the ﬁngers and bilateral sole, complete anaesthesia in the past 6 years
5+ Val424Gly; Gln442His
PTD 3 40/M BL Inﬁltration and nodules all over the body for 1 year 6.0+ Leu455Pro
PTD 4 42/M LL Left ulnar weakness, right ulnar paralysis with anaesthesia and right foot
weakness and left foot drop for 3–4 months
4.0+ Ala411Val
PTD 5 44/M LL Hypopigmented anaesthetic patches present on left thigh, sensory loss
present in B/L hand and feet; had never been treated with antileprosy drugs before
1.0+ Ala411Val
PTD 6 48/M BL Presented with type 2 reaction 5.33+ Ser437Gln
PTD 7 37/M BL Presented with type 1 reaction 4.0+ Gln438Tyr
BI, bacteriological index; BL, borderline lepromatous leprosy; LL, lepromatous leprosy; M, male.
e86 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIresistance to rifampicin. Of these seven cases, three cases
showed a mutation at codon 411 (Ala/Val) that has not been
reported previously (Table 1). Patient 1 and patient 2 had
mutations at two codon positions. All of these mutations were
in the rifampicin resistance-determining region. Genotyping of
these isolates showed that they were M. leprae type 1D, which
we have reported previously in this endemic region [6]. The BIs
of all of these new cases varied between 1+ and 6+. Resistance
to dapsone was indicated by a mutation at codon 53
(Thr/Ala) in folP in one of the new cases (Table 1).
After approximately 30 years of MDT, it is quite natural to
expect the emergence of drug resistance in M. leprae, and
hence, during the stage of elimination, it will be a major setback
to the public health programme. Drug-resistant leprosy infec-
tion can be caused by the transmission of already resistant
strains (primary resistance) or by the selection of resistance-
conferring mutations during inadequate therapy (secondary
resistance). Lavania et al. [5] indicated the presence of rifam-
picin, dapsone and oﬂoxacin resistance cases in high-endemicity
areas. M. leprae isolates that are resistant to single and multiple
drugs have been encountered. The emergence of drug resis-
tance to rifampicin will reduce the efﬁcacy of MDT, and will
result in a failure to maintain the efﬁcacy of current leprosy
control strategies around the world. Although the genome of
M. leprae has undergone massive gene decay, the rifampicin
resistance-determining region of M. leprae has been stable,
indicating the ability of M. leprae to develop resistance under
drug pressure. After 30 years of dapsone monotherapy, resis-
tance to dapsone emerged in the 1980s, and it is likely that,
after another three decades of rifampicin-based MDT, the
emergence of rifampicin resistance might be a major issue in
chemotherapy for leprosy. The ﬁndings of this study show the
emergence of resistance to rifampicin in new cases of leprosy.
The emergence of new cases with resistance to rifampicin in-
dicates that resistant strains are actively circulating in endemic
regions of India from secondary resistance cases, and infecting
the naive population at risk. This ﬁnding suggests that there is
an urgent need for the establishment of a drug resistance
monitoring policy and careful post-treatment follow-up ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcured patients, in order to detect relapse earlier and rapidly
identify strains with secondary resistance for their inclusion in a
new drug regimen. This report emphasizes the urgent need for
the inclusion of new drugs in the multidrug regimen for the
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